Department of Gastrointestinal Surgery, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
BGI Genomics, BGI-Shenzhen, Shenzhen, China.
Carcinogenesis. 2018 May 3;39(5):708-718. doi: 10.1093/carcin/bgy040.
Synchronous colorectal cancers (syCRCs), which present two or more lesions at diagnosis, are rare and pose a great challenge for clinical management. Although some predisposing factors associated with syCRCs have been studied with limited accession, the full repertoire of genomic events among the lesions within an individual and the causes of syCRCs remain unclear. We performed whole-exome sequencing of 40 surgical tumour samples of paired lesions from 20 patients to characterize the genetic alterations. Lesions from same patient showed distinct landscapes of somatic aberrations and shared few mutations, which suggests that they originate and develop independently, although they shared the similar genetic background. Canonical genes, such as APC, KRAS, TP53 and PIK3CA, were frequently mutated in the syCRCs, and most of them show different mutation profile compared with solitary colorectal cancer. We identified a recurrent somatic alteration (K15fs) in RPL22 in 25% of the syCRCs. Functional analysis indicated that mutated RPL22 may suppress cell apoptosis and promote the epithelial-mesenchymal transition (EMT). Potential drug targets were identified in several signalling pathways, and they present great discrepancy between lesions from the same patient. Our data show that the syCRCs within the same patient present great genetic heterogeneity, and they may be driven by distinct molecular events and develop independently. The discrepancy of potential drug targets and mutation burden in lesions from one patient provides valuable information in clinical management for patients with syCRCs.
同步结直肠癌(syCRCs)是指在诊断时出现两个或多个病变,较为罕见,对临床管理构成了巨大挑战。尽管已经对一些与 syCRCs 相关的潜在因素进行了有限的研究,但个体中病变之间的全基因组事件的全貌以及 syCRCs 的病因仍不清楚。我们对 20 名患者的 40 个手术肿瘤样本的配对病变进行了全外显子组测序,以表征遗传改变。同一患者的病变表现出明显不同的体细胞异常景观,并且共享的突变很少,这表明它们虽然具有相似的遗传背景,但起源和发展是独立的。经典基因,如 APC、KRAS、TP53 和 PIK3CA,在 syCRCs 中经常发生突变,并且与单发结直肠癌相比,它们大多数显示出不同的突变谱。我们在 25%的 syCRCs 中鉴定到 RPL22 中的一个复发性体细胞改变(K15fs)。功能分析表明,突变的 RPL22 可能抑制细胞凋亡并促进上皮-间充质转化(EMT)。在几个信号通路中鉴定到了潜在的药物靶点,并且它们在同一患者的病变之间存在很大差异。我们的数据表明,同一患者的 syCRCs 表现出很大的遗传异质性,它们可能由不同的分子事件驱动并独立发展。同一患者的病变之间潜在药物靶点和突变负担的差异为 syCRCs 患者的临床管理提供了有价值的信息。